Pegloticase + Methotrexate for Gout

This trial tests a treatment for gout, a type of arthritis that causes painful swelling, usually in the feet. Researchers compare two methods of administering pegloticase (an enzyme therapy)—one under the skin and one through the vein—along with methotrexate, to determine which method better manages uric acid levels in the blood. Candidates for this trial include those with gout that medication does not control well. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to a treatment that could soon become widely available.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that you must not have received prior treatment with pegloticase or similar drugs, and you must tolerate at least one standard gout flare prevention medication.

Research has shown that using pegloticase with methotrexate (MTX) is generally safe for people with gout. Studies have found that this combination helps maintain low uric acid levels, crucial for treating gout, without introducing new safety problems.

For those receiving pegloticase through an IV with MTX, recent studies identified no new safety issues. These studies also demonstrated that many patients benefited from the treatment without unexpected side effects.

When pegloticase is administered as an injection under the skin with MTX, it proves just as safe and effective as the IV method. This indicates the treatment is generally well-tolerated, with no major safety concerns reported.

Unlike the standard gout treatments, which often include medications like allopurinol or febuxostat, the investigational treatment of pegloticase combined with methotrexate offers a unique approach. Pegloticase works differently by breaking down uric acid into a more easily excreted substance, directly targeting the root cause of gout. Researchers are excited about this combination because methotrexate might enhance the effectiveness of pegloticase, potentially helping more patients achieve better control over their condition. Additionally, pegloticase is available in both subcutaneous and intravenous forms, providing flexibility in how the treatment can be administered.

This trial will evaluate the effectiveness of combining pegloticase with methotrexate (MTX) for gout treatment. Participants will receive pegloticase either subcutaneously (SC) or intravenously (IV) every two weeks, both in combination with MTX. Research has shown that this combination greatly improves gout treatment outcomes. Studies found that patients using this combination maintain lower uric acid levels more effectively than those using pegloticase alone. For the subcutaneous method, 67.2% of participants reached the desired uric acid levels by the sixth month. The intravenous method is similarly effective. Notably, adding MTX to pegloticase increases the success rate to 71%, significantly improving outcomes compared to pegloticase alone. These findings suggest that pegloticase with MTX could be a strong option for managing gout.²⁴⁶⁷⁸